|display ongoing studies|
||studied treatment||control treatment||patients||study risk of bias||sample sizes||Results|
COVID-19 mild to moderate meta-analysis
|Hung et al., 2020|
|RCT||lopinavir/ritonavir, ribavirin and interferon beta-1b||lopinavir/ritonavir||COVID-19 mild to moderate||some concern||86/41||conclusif|
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).